Vera Therapeutics (VERA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Key clinical developments and data

• Atacicept demonstrated no decline in GFR over two years in a multinational, placebo-controlled trial, setting a new standard for B-cell modulators in IgA nephropathy.

• The therapy showed high safety, with no severe infections or deaths during the COVID-19 pandemic, and over 90% patient adherence in open-label extension.

• Phase III enrollment is complete, with top-line data expected in Q2 next year, supporting a BLA filing in the second half and potential commercialization in 2026.

• The ORIGIN and PIONEER studies will expand the patient population and explore adjacent autoimmune kidney diseases.

• Atacicept’s mechanism offers a safer alternative to steroids and B-cell depleters, aiming to change the standard of care.

Competitive landscape and differentiation

• Atacicept is the only B-cell modulator with two-year GFR data, distinguishing it from competitors.

• The program uniquely tracks four endpoints, including autoantigen reduction and hematuria resolution, not traditionally used in trials.

• The data package is considered the new benchmark for efficacy and safety in the field.

• Other mechanisms are seen as less likely to match these outcomes.

Market opportunity and expansion plans

• The addressable U.S. population for IgA nephropathy is estimated at 160,000, with current trials covering about 55%.

• The PIONEER program aims to include the full IgAN population and expand to adjacent diseases like membranous nephropathy and FSGS, adding up to 70,000 more patients.

• New KDIGO guidelines and improved therapies are expected to drive more aggressive diagnosis and treatment, increasing the market size.

• Non-invasive diagnostics and collaborations, such as with the NEPTUNE Network, are being pursued to further expand reach.